Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
Med Res Rev ; 34(1): 106-35, 2014 Jan.
Article in English | MEDLINE | ID: mdl-23494977

ABSTRACT

Doxorubicin (DOX) is an anticancer anthracycline that presents a dose-dependent and cumulative cardiotoxicity as one of the most serious side effects. Several hypotheses have been advanced to explain DOX cardiac side effects, which culminate in the development of life-threatening cardiomyopathy. One of the most studied mechanisms involves the activation of DOX molecule into a more reactive semiquinone by mitochondrial Complex I, resulting in increased oxidative stress. The present review describes and critically discusses what is known about some of the potential mechanisms of DOX-induced cardiotoxicity including mitochondrial oxidative damage and loss of cardiomyocytes. We also discuss alterations of mitochondrial metabolism and the unique characteristics of DOX delayed toxicity, which can also interfere on how the cardiac muscle handles a "second-hit stress." We also present pharmaceutical and nonpharmaceutical approaches that may decrease DOX cardiac alterations in animal models and humans and discuss the limitations of each strategy.


Subject(s)
Antineoplastic Agents/adverse effects , Cardiomyopathies/chemically induced , Doxorubicin/adverse effects , Energy Metabolism , Animals , Humans , Mitochondria, Heart/drug effects , Mitochondria, Heart/physiology , Rats
2.
Curr Drug Targets ; 12(6): 850-9, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21269266

ABSTRACT

Metabolic regulation is largely dependent on mitochondria, which play an important role in energy homeostasis. Imbalance between energy intake and expenditure leads to mitochondrial dysfunction, characterized by a reduced ratio of energy production (ATP production) to respiration. Due to the role of mitochondrial factors/events in several apoptotic pathways, the possibility of targeting that organelle in the tumor cell, leading to its elimination is very attractive, although the safety issue is problematic. Berberine, a benzyl-tetra isoquinoline alkaloid extracted from plants of the Berberidaceae family, has been extensively used for many centuries, especially in the traditional Chinese and Native American medicine. Several evidences suggest that berberine possesses several therapeutic uses, including anti-tumoral activity. The present review supplies evidence that berberine is a safe anti-cancer agent, exerting several effects on mitochondria, including inhibition of mitochondrial Complex I and interaction with the adenine nucleotide translocator which can explain several of the described effects on tumor cells.


Subject(s)
Berberine/pharmacology , Mitochondria/drug effects , Neoplasms/drug therapy , Animals , Antineoplastic Agents, Phytogenic/adverse effects , Antineoplastic Agents, Phytogenic/isolation & purification , Antineoplastic Agents, Phytogenic/pharmacology , Berberidaceae/chemistry , Berberine/adverse effects , Berberine/isolation & purification , Drug Delivery Systems , Electron Transport Complex I/antagonists & inhibitors , Humans , Medicine, Traditional , Mitochondria/metabolism , Neoplasms/pathology
SELECTION OF CITATIONS
SEARCH DETAIL